Navigation Links
Novartis begins shipment of seasonal influenza vaccines to US market
Date:8/21/2013

with Fluvirin and Flucelvax to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Fluvirin or Flucelvax will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Fluvirin and Flucelvax could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novart
'/>"/>

SOURCE Novartis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Novartiss Serelaxin Has the Potential to Fulfill the Most Pertinent Unmet Needs in Acute Heart Failure by Reducing the Rate of Patient Mortality and the Rate of Worsening Renal Function
2. Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
3. Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
4. Novartis signs on to support Malaria No Mores Power of One campaign to stride towards a future without malaria
5. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
6. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
7. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
8. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
9. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
10. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
11. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
(Date:10/22/2014)... , Oct. 21, 2014   BioNano Genomics ... latest genomics research centers to purchase an ... the National Cancer Institute (NCI), NIH Intramural Sequencing ... Before Irys, obtaining a comprehensive view of a ... sequencing (NGS) does not deliver the scalability or ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics Holdings ... is revolutionizing spinal cord injury (SCI) treatment ... shown to outperform in tissue regrowth in the spinal ... Made from an FDA approved polymer, the scaffold ultimately ... harmless to the human body. NVIV has recently attracted ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... ImmusanT, Inc. announced today it has raised ... Healthcare Partners LLC to advance development of the ... monitoring tool for celiac disease. The proceeds will ... to the point of demonstrating proof-of-concept. ImmusanT expects ...
... Dec. 13, 2011 IRIDEX Corporation (Nasdaq: IRIX ... for Health and Clinical Excellence (NICE) has issued a ... is not as cost effective as conventional laser photocoagulation ... treatment for diabetic macular edema (DME), a swelling of ...
Cached Medicine Technology:ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease 2ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease 3UK's National Health System Rejects Drug Therapy for Diabetic Macular Edema 2UK's National Health System Rejects Drug Therapy for Diabetic Macular Edema 3
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... length may be showing a genetic propensity for obesity as ... have been linked to increased body fat, but the same ... muscle, the researchers said. At 1 year, kids with ... and 3, however, these genes were linked to excessive weight ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... Parker Named Interim Chief Financial Officer , , ... MDTH ), a healthcare provider focused on high ... cardiovascular disease, today announced that Art Parker, Senior Vice ... Financial Officer. Parker replaces Jeff Hinton, whose employment ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that it will ... 10, 2009 at 4:30 pm Eastern Time. Dave Holveck, President and ... programs. , , The presentation will be webcast live and can ... the investors section. , , About Endo ...
... Scientists make strides in finding ways to slow tumor ... A protein called PHD2 that regulates blood vessel growth ... researchers who analyzed levels of the protein in tumor ... expression of PHD2, researchers at Stanford University School of ...
... CORAL GABLES, FL (June 5, 2009)--Dengue Fever (DF) and ... viral diseases in the World. Around 50-100 million cases ... of suffering this debilitating and sometimes fatal disease. Dengue ... an interdisciplinary team of researchers from the University of ...
... Interleukin Genetics, Inc. (NYSE Amex: ... President of Research and Development, will present findings that ... to weight-loss in overweight individuals at the American Diabetes ... Aziz will present the Company,s research at 8 a.m. ...
... --- Neighborhoods with restaurants, entertainment, cultural facilities and ethnic ... Chicago than neighborhoods where residents are less likely to ... facilities. , Published in the spring 2009 ... Immunology , the two-year study led by Ruchi Gupta, ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference 2Health News:Researchers develop the first climate-based model to predict Dengue fever outbreaks 2Health News:Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting 2Health News:Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting 3Health News:Asthma rates and where you live 2
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid NH, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: